LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trialD. Schadendorf, E. Livingstone, Thomas Eigentler et al.|Annals of Oncology|2024Cited by 3
Impact of Antithrombotic Therapy on Survival Outcomes in Advanced Melanoma Patients Receiving Targeted Therapy: Insights from the Prospective Multicenter ADOReg RegistryNick Zimmermann, Christoffer Gebhardt, Julian Kött et al.|EJC Skin Cancer|2025Cited by 0